Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Therapy vs PDT+IVTA in AMD CNV
NCT00930189Phase 3Withdrawn
- Sponsor
- Asociación para Evitar la Ceguera en México
- Start
- Apr 2006
- Primary completion
- Apr 2006
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Asociación para Evitar la Ceguera en México. Planned start Apr 2006; status: withdrawn.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00930189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00930189.